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Due to the critical role of cyclooxygenase (COX) enzymes in the complex process of inﬂammation, their inhibition has formed part of the basic
therapeutics used in the treatment of inﬂammation in humans. Medicinal plants have been widely explored in the search for remedies for pain-
related ailments. The bulb/corm and leaf extracts of four medicinal bulbs, Tulbaghia violacea, Hypoxis hemerocallidea, Drimia elata andMerwilla
plumbea, commonly used in the treatment of pain-related ailments in South African traditional medicine, were evaluated for their ability to inhibit
cyclooxygenase (COX-1 and COX-2) enzymes. The plant materials were collected in spring, summer, autumn and winter seasons, with a view of
assessing the dynamics of their medicinal properties in different seasons. The dried plant materials were extracted with petroleum ether (PE),
dichloromethane (DCM), 80% ethanol (EtOH) and water. All the PE and DCM extracts (at ﬁnal concentrations of 0.25 mg/ml) in all the tested
plant samples recorded between moderate (40–70%) and high (>70%) COX-1 and COX-2 inhibition levels across all seasons. The ethanol extracts
of corms of H. hemerocallidea also demonstrated moderate to high inhibitory activity against COX-1 enzyme across all seasons. The ethanol ex-
tracts of bulb and leaf samples of T. violacea showed selective inhibitory activity for COX-2 enzyme in all the seasons. The highest COX inhib-
itory levels were recorded against COX-2 from the PE leaf (spring) and bulb (autumn) extracts of T. violacea, with both recording 100% inhibitory
activity. Thus the material collected in any season can be considered to be similarly effective.
© 2011 SAAB. Published by Elsevier B.V. All rights reserved.
Keywords: Anti-inﬂammatory; Cyclooxygenase inhibition; Medicinal bulbs; Seasonal variation1. Introduction
Plants cannot escape from the environmental extremes of
light, temperature, and drought, nor move to regions with better
nutritional conditions, and have thus evolved highly complex
mechanisms to integrate physiology and metabolism in order
to adapt to the conditions to which they are exposed. Secondary
metabolites form an integral component of these adaptive
mechanisms. External factors quantitatively affect secondary⁎ Corresponding author. Tel.: +27 33 2605130; fax: +27 33 2605897.
E-mail address: rcpgd@ukzn.ac.za (J. Van Staden).
0254-6299/$ - see front matter © 2011 SAAB. Published by Elsevier B.V. All righ
doi:10.1016/j.sajb.2011.09.011metabolic processes through their effects on plant development,
growth rates and partitioning of metabolites to the secondary
metabolite of interest. These factors can also trigger abrupt ac-
tivation of qualitative changes in secondary metabolite produc-
tion (Laughlin, 1993; Lommen et al., 2008). Climatic (abiotic)
factors often have an especially large influence on the biosyn-
thetic levels and quality of secondary metabolites in plants
(Coley, 1987). Since medicinal plant extracts derive their ther-
apeutic effects from these secondary metabolites, an insight
into the seasonal dynamics of the pharmacological properties
of medicinal plants is basic to the understanding of when to col-
lect them for medicinal use. Coinciding medicinal plant har-
vesting with maximum biological activity of a particular plant
species would serve as a way for the more effective utilisation
of plant-based medicine.ts reserved.
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volved in inflammatory processes, these enzymes have since
become the research targets for drug development in the treat-
ment of inflammation. Prostanoid biosynthesis is inhibited by
nonsteroidal anti-inflammatory drugs (NSAIDs) that are widely
prescribed as analgesics and anti-inflammatory agents. Treat-
ment with NSAIDs inhibits the production of prostaglandins
and down-regulates inflammation-related pathological symp-
toms such as pain and swelling. The use of NSAIDs however,
results in major changes to the pathophysiological functions
of the body leading to some side effects such as gastric and
renal ulceration, irritation and bleeding (Botting, 2006; Oshima
et al., 1996). It is for these undesirable side effects associated
with the use of NSAIDs that research interest into alternative
forms of anti-inflammatory agents has been stimulated. Medic-
inal plants offer a vast biogenic resource base for exploitation in
the discovery of innovative anti-inflammatory agents. Several
natural plant-derived compounds such as flavonoids, saponins,
tannins, alkaloids and essential oils have possess some anti-
inflammatory activities (Gurib-Fakim, 2006; Just et al., 1998).
Plant-derived natural products are therefore important in the
search for anti-inflammatory agents.
In view of this fact, four medicinal bulbs used in the treat-
ment of pain-related ailments in South African traditional med-
icine were evaluated for their seasonal variation in the
inhibition of COX-1 and COX-2 enzymes, which are involved
in the biosynthesis of prostaglandins in inflammation
processes.
2. Materials and methods
2.1. Plant material
The plant materials used in this study were collected in Sum-
mer (December), Autumn (March), Winter (June) and Spring
(September) from the University of KwaZulu-Natal Botanical
Garden, Pietermaritzburg, South Africa and separated into
bulbs and leaves. Voucher specimens (Table 1) were deposited
in the University of KwaZulu-Natal Herbarium (NU), Pieter-
maritzburg. The samples were then dried in an oven at a con-
stant temperature of 50 °C for five days and ground into fine
powders.Table 1
Medicinal plants used in this study and their traditional medicinal uses.
Family Species Voucher
number
Medicinal uses
Alliaceae Tulbaghia violacea Harv. NCUBE
04 NU
Bulbs and leaves are used
tuberculosis, colds and fev
2006; Van Wyk et al., 200
Hypoxidaceae Hypoxis hemerocallidea
Fisch. Mey & Avé-Lall
NCUBE
01 NU
Plant decoctions have purg
inflammation, testicular t
(Watt and Breyer-Brandwi
Hyacinthaceae Drimia elata Jacq NCUBE
03 NU
Bulbs are used to treat ur
infections and diseases of
Hyacinthaceae Merwilla plumbea (Lindl.)
Speta
NCUBE
02 NU
Decoctions are used for
rejuvenating the body. Enh2.2. Preparation of plant extracts
The samples were sequentially extracted with 20 ml/g of pe-
troleum ether (PE), dichloromethane (DCM), 80% ethanol
(EtOH) and water in a sonication bath containing ice for 1 h.
The crude extracts were then filtered under vacuum through
Whatman No. 1 filter paper and the organic extracts were con-
centrated in vacuo at 35 °C using a rotary evaporator. The con-
centrated extracts were subsequently dried at room temperature
under a stream of air. Water extracts were freeze dried and kept
in airtight containers.
2.3. Cyclooxygenase (COX-1 and COX-2) inhibitory bioassays
The COX inhibitory activity of plant extracts were evaluated
against COX-1 and COX-2 as described in Jäger et al. (1996)
and Zschocke and Van Staden (2000) respectively. The COX-
1 and COX-2 (Sigma-Aldrich) enzymes were activated with a
co-factor solution and pre-incubated on ice for 5 min. The en-
zyme/co-factor solution (60 μl) was added to the sample solu-
tion (2.5 μl, 10 mg/ml) and pre-incubated for 5 min at room
temperature. To the test samples, [14C] arachidonic acid
(20 μl) was added and incubated at 37 °C for 10 min. After in-
cubation, the reaction was terminated by adding HCl (10 μl,
2N). Four controls were included. Two were background in
which the enzyme was inactivated with HCl before the addition
of [14C] arachidonic acid, and two were solvent blanks. Indo-
methacin was used as a positive control at a final concentration
of 5 μM for COX-1 and 200 μM for COX-2. Organic extracts
were evaluated at a final concentration of 0.25 mg/ml and
water extract at 2 mg/ml. Percentage inhibition of the extracts
was calculated by comparing the amount of radioactivity pre-
sent in the sample to that in the blank solvent. Results are pre-
sented as means±standard errors of two independent
experiments; each experiment was done in duplicate.
2.4. Statistical analysis
Data on percentage inhibition activity for each extracting
solvent in each plant sample in the four different seasons
were arcsine transformed and subjected to one-way analysis
of variance (ANOVA) using GenStat 12th edition (VSNin the treatment of stomach pains, asthma, constipation, oesophageal cancer,
er, HIV/AIDS opportunistic infections (Hutchings et al., 1996; Crouch et al.,
9; Klos et al., 2009).
ing effects and boost the immune system. Corms are used for the treatment of
umours, urinary complaints, cancer and HIV/AIDS opportunistic infections
jk, 1962; Crouch et al., 2006).
inary infections, diseases of the uterus, pain, feverish colds, coughs, urinary
the uterus (Hutchings et al., 1996; Van Wyk et al., 2009).
wound healing, boils, sores, sprains, removing scar tissue, cleaning and
ances, male potency and libido (Crouch et al., 2006; Van Wyk et al., 2009).
248B. Ncube et al. / South African Journal of Botany 78 (2012) 246–251International, UK). Significantly different means were separat-
ed using the Least Significant Difference (LSD) technique
(P≤0.05) and results presented as means±standard errors.
3. Results and discussion
The percentage inhibition of the COX-1 enzyme by four
bulb and four leaf extracts from material collected in different
seasons is presented in Table 2. There were no leaf samples
for D. elata in winter because the plant shed its leaves during
this period. The COX inhibitory activity was defined at four
levels, with activity below 20% being considered insignificant,
20–40% low, 40–70% moderate, and 70–100% high (Tunón et
al., 1995). With the exception of the corm extracts of H.
hemerocallidea and bulb extracts of M. plumbea in autumn,
all the PE extracts showed high inhibition (%) levels (>70%)
in all seasons. Of the DCM extracts, only extracts from T.
violacea bulbs and D. elata leaves showed high inhibitory
activity across all the seasons. All the other DCM extractsTable 2
COX-1 enzyme inhibitory activity (%) of bulb/corm and leaf extracts of T. violac
autumn and winter seasons.
Plant species Plant
part
Extract Inhibitio
Spring
Tulbaghia violacea Bulb PE 88.5±2.
DCM 90.4±2.
EtOH 0.00a
Water 0.00a
Leaf PE 94.7±2.
DCM 89.1±1.
EtOH 25.6±2.
Water 0.00a
Hypoxis hemerocallidea Corm PE 90.5±2.
DCM 77.4±2.
EtOH 66.0±4.
Water 0.00a
Leaf PE 77.5±4.
DCM 87.9±2.
EtOH 12.8±3.
Water 0.00a
Drimia elata Bulb PE 84.6±1.
DCM 68.2±2.
EtOH 7.10±0.
Water 12.2±0.
Leaf PE 90.9±4.
DCM 73.8±4.
EtOH 1.22±0.
Water 0.00a
Merwilla plumbea Bulb PE 85.0±3.
DCM 82.4±4.
EtOH 0.00a
Water 0.00a
Leaf PE 90.0±2.
DCM 83.3±3.
EtOH 0.00a
Water 0.00a
Values in a row with different letters are significantly different at P≤0.05 (n=4).
PE = petroleum ether, DCM = dichloromethane, EtOH = 80% ethanol.
COX-1 inhibition (%) by indomethacin at a final concentration of 5 μM was 61.3±
Organic extracts were tested at a final concentration of 0.25 mg/ml and water extracdisplayed moderate to high (>40%) inhibitory activity in all
seasons. The highest COX-1 inhibitory activity (99.8%) was
recorded from the PE extracts of T. violacea bulbs in winter.
In all the extracts that showed some level of inhibition, there
was significant variation in this activity from season to season.
Although the inhibitory activity of PE and DCM extracts
against COX-1 enzyme varied significantly from season to sea-
son, the activity fluctuated between moderate to high levels. As
an adaptation for survival and growth within changing environ-
mental conditions, plants have evolved different morphological
and chemical traits (Wink, 2003). This has resulted in different
types and quantities of chemical compounds being produced by
plants in different seasons (Ncube et al., 2011). Pharmacologi-
cal and phytochemical screening of M. plumbea bulbs revealed
that dichloromethane and hexane extracts have good COX-1
and COX-2 inhibitory properties, owing to the presence of sa-
ponins and bufadienolides (Sparg et al., 2002). The concentra-
tions of active compound(s) responsible for the anti-
inflammatory activity could therefore fluctuate with seasons.ea, H. hemerocallidea, D. elata and M. plumbea collected in spring, summer,
n (%)
Summer Autumn Winter
15a 96.5±1.43b 91.8±2.61a 99.8±1.18b
54a 95.1±4.60b 88.7±1.58a 94.3±3.80b
0.00a 0.00a 0.00a
0.00a 0.00a 0.00a
02c 88.2±3.73b 79.5±3.20a 81.8±3.74a
66b 50.3±3.55a 88.1±3.92b 91.4±4.31b
22a 27.3±2.13a 33.1±1.11b 29.3±3.50ab
0.00a 0.00a 7.71±2.81b
89b 89.3±1.37b 49.5±2.54a 87.2±1.58b
96c 52.3±4.57a 78.8±0.71c 71.6±3.90b
32a 67.7±5.14a 74.5±4.12a 86.9±5.97b
0.00a 0.00a 0.00a
12b 80.2±0.07c 70.8±1.24a 76.0±2.91b
18c 60.0±2.61a 70.6±2.37b 57.2±3.02a
60a 10.8±3.50a 13.6±4.22a 8.80±3.11a
0.00a 0.00a 0.00a
73b 88.1±1.99c 73.7±3.12a 94.1±2.42d
41b 59.2±1.93a 58.0±1.65a 83.1±1.78c
09c 9.80±3.23c 3.42±1.03b 1.67±0.18a
36c 9.10±2.11b 11.1±1.21bc 5.12±0.56a
57b 90.9±0.30b 75.4±3.29a –
36ab 70.3±0.88a 75.5±0.53b –
14b 0.00a 0.00a –
0.00a 0.00a –
67c 82.0±2.16c 68.9±1.40a 78.2±0.87b
42c 83.9±1.35c 68.3±1.31b 43.6±2.51a
0.00a 0.00a 0.00a
0.00a 0.00a 0.00a
20b 91.1±2.19b 93.0±1.31b 83.9±2.16a
48c 55.8±2.57a 85.2±2.31c 62.1±0.85b
3.70±3.95b 4.10±0.93b 0.00a
0.00a 4.11±0.07c 1.30±0.11b
2.18%.
ts at 2 mg/ml.
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tivity (moderate to high levels) in this study, the activity was
maintained at these levels (>40%) in all seasons. This trend,
therefore, may justify the collection and use of these extracts
for treatment of pain-related ailments in traditional medicine
in any of the seasons.
Although water extracts were tested at a higher concentra-
tion (2 mg/ml) than organic extracts (0.25 mg/ml) in this bioas-
say, all water and ethanol extracts, except for the ethanol
extracts of H. hemerocallidea corms and T. violacea leaves,
displayed insignificant to low COX-1 inhibitory activity. The
extracts of H. hemerocallidea (corm) were the only ethanol ex-
tracts that showed moderate to high activity across all the sea-
sons. The low activity shown by the water and ethanol
extracts in this study is consistent with other previous findings
on similar and other plant species (Gaidamashvili and Van
Staden, 2006; Jäger et al., 1996; Sparg et al., 2002). The mod-
erate to high inhibitory activity of PE and DCM extracts
towards COX-1, suggest that lipophilic compounds are in-
volved in the enzyme inhibition process. Lipophilic compounds
have good resorption through the cell membrane even at lower
concentrations compared to polar compounds (Zschocke and
Van Staden, 2000). These compounds are seldom found, and
if they are, they are often in very minute quantities in water ex-
tracts (Tunón et al., 1995). This therefore, explains the high ac-
tivity of these extracts in spite of the low extract yields obtained
when using lipophilic extraction solvents.
Inflammation is a complex pathophysiological process that
involves an interaction of a variety of signalling molecules
and mediators in a series of enzyme catalysed reactions
(White, 1999). Lack of inhibitory activity of the water extracts
in the COX-1 inhibitory assay does not necessarily disqualify
these extracts as possibly having anti-inflammatory activity.
Plant extracts exert their enzyme inhibitory effects through a
spectrum of different modes of action and target sites (Capone
et al., 2007). It is possible, therefore, that the active compounds
in the water extracts could have an effect at alternative sites in
the complex inflammation process. A number of other studies
with different plant species have reported good COX-1 inhibi-
tory activity from water extracts (Jäger and Van Staden, 2005;
Taylor and Van Staden, 2001).
The COX-1 enzyme is expressed constitutively in most tis-
sues and catalyses the production of prostaglandins involved
in the prostanoid-mediated physiological functions such as
gastric cytoprotection, maintenance of renal homeostasis, and
normal platelet functions (Morita, 2002). Findings suggest
that COX-1 has an important role in pain processing and sen-
sitisation in the rat spinal cord after surgery (Zhu et al., 2003).
Complete COX-1 inhibition is generally associated with some
detrimental side effects. Because of these side effects, such as
the damage to the gastrointestinal tract, anti-inflammatory
agents with high COX-1 inhibitory activity are less desirable
(Anderson et al., 1996). Although plants screened in this
study showed good COX-1 inhibition, considering these side
effects, extracts with moderate activity may be preferable to
use rather than those with high activity. Prolonged use of
plant extracts with high inhibitory activity may result in themanifestation of the damaging side effects (Smith et al.,
1998).
Table 3 shows the COX-2 inhibitory activity of plant ex-
tracts. The PE and DCM extracts of both bulb and leaf extracts
of all the screened plant extracts showed good inhibitory activ-
ity (>40%) in all seasons. However, the PE and DCM bulb ex-
tracts of T. violacea and D. elata and DCM corm extracts of H.
hemerocallidea displayed high inhibitory levels in all the sea-
sons. Although the inhibition levels varied significantly from
season to season, extracts from bulbs of T. violacea (PE,
DCM, EtOH) and D. elata (PE, DCM) showed consistently
high (73.7% to 100%) inhibition levels in all seasons.
The highest inhibitory activity was recorded in the PE ex-
tracts of T. violacea bulbs and leaves with both having 100%
inhibition in autumn and spring, respectively. The results for
the COX-2 inhibitory activity followed a somewhat similar
trend as those of COX-1. Among the ethanol extracts, good
COX-2 inhibitory activity was recorded from the T. violacea
bulb and leaf extracts, with both exhibiting consistently high
and moderate activity respectively, across all seasons. All
water and a significant number of ethanol extracts showed in-
significant activity. In most of the plant species, extracts of
the plant material gathered in winter appeared to have lower ac-
tivity compared to the activity of those gathered in the other
seasons. This could have been due to the senescing leaf tissues
and the onset of dormancy in the bulbs/corms. The biochemical
activity rate, and consequently the production of compounds in
plants, decreases drastically during dormancy and tissue senes-
cence (Bidwell, 1974).
The inducible COX-2 enzyme is thought to be responsible
for the accumulation of prostaglandins in most acute inflamma-
tions (Vane et al., 1998). However, there is increasing evidence
that in some tissues such as the brain, reproductive organs (ova-
ries, uterus), kidney, and placenta, COX-2 is also synthesised at
a constant rate, and is responsible for the synthesis of prosta-
noids responsible for the regulatory and homeostatic functions
in these tissues (Hinz and Brune, 2002; Mitchell and Warner,
2006). Anti-inflammatory agents with selective COX-2 inhibi-
tion are often more desirable as they attenuate the damaging
side effects associated with the inhibition of COX-1. Interest-
ingly, ethanol extracts of both bulbs and leaves of T. violacea
showed higher inhibitory activity (51.2% to 83.9%) towards
COX-2 compared to very low to insignificant levels (0 to
33.1%) for COX-1. The ethanol bulb extracts of T. violacea
maintained high inhibitory levels (79.7 to 83.9%) in all seasons,
while leaf extracts had moderate (51.2 to 63.6%) activity. The
two extracts could contribute to the development of remedies
with specific COX-2 activity as this remains a considerable
challenge. The important pharmacological and biological dif-
ferences between COX-1 and COX-2 enzymes are attributed
to the small differences in their structure. The active site of
COX-2 is larger than that of COX-1 (Gierse et al., 1996). The
development of COX-2 specific inhibitors therefore, in part,
utilises this characteristic (Habeeb et al., 2001). High COX-2
inhibitory activity in the ethanol extracts of T. violacea bulbs
and leaves compared to COX-1, may be an indication that the
active compound(s) in these extracts are specific targets of the
Table 3
COX-2 enzyme inhibitory activity (%) of bulb/corm and leaf extracts of T. violacea, H. hemerocallidea, D. elata and M. plumbea collected in spring, summer,
autumn and winter seasons.
Plant species Plant
part
Extract Inhibition (%)
Spring Summer Autumn Winter
Tulbaghia violacea Bulb PE 94.3±0.90a 99.7±1.79b 100±00b 99.4±0.01b
DCM 97.9±3.48b 90.7±3.43a 98.0±0.17b 89.1±0.38a
EtOH 83.5±3.18b 81.4±2.21a 83.9±0.71b 79.7±0.04a
Water 0.00a 0.00a 0.00a 0.00a
Leaf PE 100±00c 83.2±2.01b 82.3±3.51b 58.2±4.38a
DCM 91.5±2.38c 40.1±1.29a 93.2±1.49c 62.0±4.73b
EtOH 63.6±2.06c 59.8±0.66b 61.4±2.03b 51.2±1.11a
Water 0.00a 1.23±0.89b 0.00a 0.00a
Hypoxis hemerocallidea Corm PE 85.7±1.61d 80.1±1.79c 68.1±1.54b 63.2±4.42a
DCM 86.5±0.33b 88.1±2.11b 88.6±2.02b 82.6±1.25a
EtOH 0.00a 0.00a 0.00a 0.00a
Water 12.4±0.56c 14.0±1.86d 10.2±1.00b 6.20±0.80a
Leaf PE 80.3±3.71c 79.4±0.61c 70.6±1.26b 51.0±2.50a
DCM 73.1±2.21c 69.2±2.74c 63.8±5.21b 49.3±2.25a
EtOH 8.08±1.74b 11.5±1.51c 7.81±2.11b 4.56±0.84a
Water 0.00a 0.00a 0.00a 0.00a
Drimia elata Bulb PE 73.7±2.58a 83.2±2.31b 86.3±1.00c 88.9±0.08c
DCM 90.8±1.51b 89.7±1.93b 91.2±2.33b 79.4±2.20a
EtOH 5.41±1.25a 8.11±0.89b 11.0±2.88c 6.11±1.79a
Water 2.31±1.22a 5.69±0.61b 6.12±0.92b 2.11±0.85a
Leaf PE 85.2±3.69b 81.3±1.19b 65.8±2.40a –
DCM 80.3±1.20c 52.8±0.98a 62.3±0.40b –
EtOH 0.00a 0.00a 0.00a –
Water 0.00a 0.00a 0.00a –
Merwilla plumbea Bulb PE 80.1±6.40c 71.5±2.29b 55.0±4.74a 51.2±0.82a
DCM 76.1±1.59c 65.1±3.06b 56.4±3.05a 58.9±3.72a
EtOH 0.00a 0.00a 0.00a 0.00a
Water 0.00a 0.00a 0.00a 0.00a
Leaf PE 85.1±1.00b 91.7±0.34c 100±00d 61.8±3.54a
DCM 78.1±0.27c 82.7±3.94d 67.1±0.24b 58.4±0.76a
EtOH 0.00a 0.00a 0.00a 0.00a
Water 0.00a 0.00a 0.00a 0.00a
Values in a row with different letters are significantly different at P≤0.05 (n=4).
PE = petroleum ether, DCM = dichloromethane, EtOH = 80% ethanol.
COX-2 inhibition (%) by indomethacin at a final concentration of 200 μM was 65.2±2.74%.
Organic extracts were tested at a final concentration of 0.25 mg/ml and water extracts at 2 mg/ml.
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induce selectivity through interaction with the secondary pock-
et of COX-2 which is absent in COX-1 (Habeeb et al., 2001).
The secondary pocket present in COX-2 has been attributed
to the presence of isoleucine (Ile523) in COX-1 relative to the
smaller valine (Val523) in COX-2 (Luong et al., 1996). It is
therefore, an interaction between the active site chemistry and
that of the molecular inhibitor that determines selectivity. Etha-
nol extracts of T. violacea may thus be promising anti-
inflammatory agents with a reduced risk of serious gastrointes-
tinal side effects. The active compounds in these extracts may
be inhibiting the COX-2 enzyme through this unique secondary
pocket site.
4. Conclusions
In all plant species screened in this study, the inhibitory ac-
tivity of both bulb and leaf extracts were comparable, with both
plant parts exhibiting good activity (moderate to high levels) in
PE and DCM extracts. The results from this study supports thetraditional use of the four plant species in the treatment of pain-
related ailments such as, gastro-intestinal ailments, stomach
ache, wounds, urinary tract infections and cancer. The COX
bioassay is an example of a mechanism-based assay that utilises
subcellular structures (enzymes) to detect inhibitors of inflam-
mation (Noreen et al., 1998). The actual inflammation process
in living tissues is, however, very complex and involves a series
of mediators and various other enzymes. In this regard, the in
vitro effects of an extract should be appreciated as supporting
evidence only, since the in vivo effects may be complicated
by a plethora of chemical, physical and physiological factors.
In vivo tests are required to validate the effects of these extracts
in living organisms. Ethanol extracts of T. violacea offer pros-
pects for the development of COX-2 selective inhibitors. Re-
search aimed at identification and possible isolation of the
active compound(s) in these extracts, and testing them further
in in vivo models could be a significant breakthrough in allevi-
ating the detrimental effects of COX-1 inhibition by NSAIDs.
Considering the aspect of conservation of these medicinal
plants, and in light of the comparable anti-inflammatory
251B. Ncube et al. / South African Journal of Botany 78 (2012) 246–251activity of their bulb/corm and leaf extracts, leaves may thus
substitute for bulbs in the treatment of inflammation ailments.
This could offer a practical strategy in the conservation of
these medicinal plants from the wild. Harvesting of leaves is
considered less destructive than the underground parts, al-
though intensive pruning can affect reproductive performance.
Based on these results, both leaves and bulbs/corms of these
plants can be harvested for use in the treatment of pain-
related ailments irrespective of the season.
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